Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

r treatment period in the 36-month group and 13% in the 12-month group(1).

Novartis provided the study drug and supported the study financially. Additional funding was received from the Academy of Finland, Cancer Society of Finland, Sigrid Juselius Foundation and Helsinki University Research Funds.

About Gleevec
Gleevec® (imatinib mesylate) tablets are indicated for the treatment of patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) that are cancerous, cannot be surgically removed, and/or have spread to other parts of the body. Gleevec is also approved for use after surgery in patients that have had their KIT (CD117)-positive GIST completely removed.

Gleevec Important Safety Information
Gleevec can cause fetal harm when administered to a pregnant woman. Women taking Gleevec should not become pregnant, and should be advised of the potential risk to the unborn child.

Gleevec is often associated with edema (swelling) and serious fluid retention. Studies have shown that edema (swelling) tended to occur more often among patients who are 65 and older or those taking higher doses of Gleevec.

Cytopenias (reduction or lack of certain cell elements in blood circulation), such as anemia, have occurred. If the cytopenia is severe, your doctor may reduce your dose or temporarily stop your treatment with Gleevec.

Severe congestive heart failure and left ventricle dysfunction have been reported, particularly in patients with other health issues and risk factors. Patients with heart disease or risk factors or history of renal failure will be monitored and treated for the condition.

Severe liver problems (hepatotoxicity) may occur. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of Gleevec.

Bleeding may occur. Severe gastrointestinal (GI) bleeding has been reported in
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Instrumentation Laboratory (IL) today announced the launch of its ... is part of a comprehensive rebranding effort by Werfen, the ... Boston, MA , in 1959, IL has been part ... companies in the group include Inova Diagnostics ( San ... Spain ).  Like IL, these three companies are focused ...
(Date:7/29/2014)... Research and Markets has announced the addition ... report to their offering. ... medical device used to provide medication or assist a ... achieve adequate oxygen levels to maintain life. Patients with ... ARDS require the need of respiratory devices. The medication ...
(Date:7/29/2014)... , July 29, 2014  Based on its ... (PERS) market, Frost & Sullivan recognizes MobileHelp with ... for Price Performance Value Leadership. MobileHelp,s leadership in ... expectations for tech progression in personal emergency response, ... these solutions. MobileHelp is at the ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... Horizon Pharma, Inc. announced today that it has filed a registration statement ... a proposed initial public offering of shares of its common stock.  All shares ... by the Company. , , , ... & Company, Inc. and Piper Jaffray & Co. are acting as ...
... Pharmaceuticals (NYSE: WPI ) today announced that ... as Senior Vice President, Global Operations, has been promoted to Executive Vice ... Bisaro , President and Chief Executive Officer of Watson. , ... Mr. Stewart will assume responsibility ...
Cached Medicine Technology:Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering 2Watson Promotes Robert Stewart to Executive Vice President, Global Operations 2Watson Promotes Robert Stewart to Executive Vice President, Global Operations 3
(Date:7/29/2014)... 2014 DailyGossip.org reveals in its latest review ... who can perfectly understand patients and what they have to ... Gadsby is the author of the new program. Ellie claims ... of suffering, Ellie started her very own research. Four years ... The author of the Get Rid of Cold Sores program ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural ... created by a popular nutritionist and health specialist. Michael ... for this disorder, but none of them worked. , ... of having to look for an alternative vitiligo treatment, ... this method, too, to become vitiligo free. , ...
(Date:7/29/2014)... 2014 For survivors of severe combat injuries threatening ... flaps have a good record of safety and effectiveness ... issue of Plastic and Reconstructive Surgery ... Society of Plastic Surgeons (ASPS). , Experience with ... and Afghanistan shows good success rates, with no increase ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... NH (July 29, 2014) Using quality improvement measures ... New England Cardiovascular Disease Study Group, researchers have found ... a procedure with contrast dye. , Currently, 7-15 percent ... with contrast-dye end up with kidney injury, which can ... leading to temporary or permanent dialysis, says a study ...
Breaking Medicine News(10 mins):Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2
... Doctor, Health officials of the NHS Grampian said that people ... // The NHS health board said so defending their decision ... wards. ,A spokeswoman for NHS Grampian said a ... be suitable for a patient to stay outwith the city's ...
... is a fungal infection affecting mostly children in North America. ... affected by ringworm infections. //It is a highly contagious skin ... symptoms such as scaly scalp and hair loss which can ... household pets but in rare occasions it is passed easily ...
... The authorities in Delhi have blamed the poor quality of ... the last four months. So far 222 cases have been ... against 92 in the corresponding period last year. But we ... well under control," said N.K. Yadav, deputy municipal health officer ...
... Zealand have warned against using traditional Indian medicines after ... reported Friday.// ,"We wish to alert the medical ... a particular form of herbal remedy, namely, Ayurvedic medicine," ... Zealand Medical Journal. ,The eight patients suffered ...
... Delhi High Court has demanded an explanation from the medical ... boy suffering from cancer got inflicted with AIDS after undergoing ... an explanation on why the relevant documents were not being ... Sen ruled that the blood transfusion was the business of ...
... In the event of an influenza pandemic set into action by ... are we to handle// a mega crisis, and what plan of ... the responses to an epidemic, eight Asia Pacific countries are teaming ... gauge the effectiveness of a global response to a pandemic. ...
Cached Medicine News:
ELISA for detection of Anti-Gliadin IgA....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgA antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
... immunosorbent assay method for the semi-quantitative determination ... human serum. The results of the anti-Gliadin ... aid in the diagnosis of diseases associated ... Coeliac Disease. Levels of these autoantibodies are ...
Medicine Products: